Discovering New Therapies for AMD
The Molecular Ophthalmology Laboratory, under the direction of Dr. Karl Csaky, Managing & Medical Director at the Retina Foundation of the Southwest, is studying live cell cultures to investigate new potential drug treatments for age-related macular degeneration (AMD). Live cultures offer a quick and scalable solution for testing new drugs and therapies for AMD. Here, Dr. Catchpole and Dr. Kularatne, examine the growth of retinal pigment epithelial cells using an EVOS XL microscope. Using these retinal cells ensures that we develop a system in the culture dish that reflects the disease state.
For a closer look at the cells, we utilize the technique of immunofluorescence. This process allows us to tag specific parts of the cells with fluorescent markers. These tags can then be analyzed with the confocal microscope installed in the lab. Here, Dr. Catchpole analyzes the expression of Zo-1, a protein expressed in the boundaries between the retinal cells. The use of these fluorescent markers allows us to analyze the changes occurring in the retinal cells in AMD at a molecular level. Our goal is to discover the best possible drug treatment for damaged retinal cells, and potential new therapies to treat AMD.
Related Articles
Retina Foundation Completes $3.7M Capital Campaign Who Are The Brothers In Toyota’s Super Bowl 2022 Commercial? National Eye Institute Awards $949,804 for a 5-Year Study of RP iPad App for Detecting Retinal Disease Receives Second FDA Approval Promising Results From Ongoing Phase 1/2 Clinical Trial for X-Linked Retinitis Pigmentosa (XLRP)